|
hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III. |
2010-12-28 |
CIM |
|
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin. |
2010-12-29 |
CIM |
|
Patients with non small cells lung cancer (NSCLC) and brain metastasis. |
2010-12-29 |
CIM |
|
14F7 MAb marked with Tc99 Phase II in breast tumors. |
2010-12-29 |
CIM |
|
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III. |
2010-12-27 |
CIM |
|
Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I. |
2010-12-17 |
CIM |
|
NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II |
2010-12-17 |
CIM |
|
Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors. |
2010-12-17 |
CIM |
|
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors |
2013-06-19 |
CIM |
|
CIMAvax-EGF vaccine Predictor Phase IV |
14/12/2015 |
CIM |
|
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors |
17/02/2017 |
CIM |
|
EC122 HER-1 Prostate Phase I |
15/11/2016 |
CIM |
|
hR3 in metastatic or recurrent colorectal cancer |
22/11/2013 |
CIM |
|
CIMAVax EGF in Lung Cancer in PHC. Phase IV |
05/08/2014 |
CIM |
|
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II |
22/04/2016 |
CIM |
|
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV |
30/06/2016 |
CIM |
|
NeuroEPO in patients with Parkinson disease stage II-III |
01/02/2017 |
CIM |
|
CIMAvax-EGF in Bladder cancer |
11/08/2020 |
CIM |
|
VSSP in renal cell carcinoma |
08/04/2021 |
CIM |
|
Post EUA study of Itolizumab in COVID-19 |
21/03/2022 |
CIM |
